Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your account with SnapTrade.
August 2020, Teva Pharmaceutical Industries Limited (“Teva”) received approval from the U.S. Food and Drug Administration to market an off-patent version of Korlym, a best-selling Corcept product. Then on February 20, 2025, Seeking Alpha reported that a group of health insurers had filed a lawsuit against Corcept in California, accusing Corcept of manipulating the patent process in its efforts to “vigorously enforce” its intellectual property rights linked to Korlym, in an effort to stifle Teva’s generic product launch.
Following this news, Corcept’s stock price fell over 11% on the same day.